Secondary relevance to vitamin D This paper mainly addresses another topic and also reports a vitamin D analysis, result or scientific synthesis.
This paper mainly addresses another topic and also reports a vitamin D analysis, result or scientific synthesis.
Why this paper is included
Supporting source evidence:
All patients at study onset were on Folic acid, L-carnitine and Vitamin D and Hydroxyurea as standard of care.Baseline demographic, laboratory, and treatment data of studied NTDT patientsMetformin group(n = 20)Control group(n = 22)P-valueDemographic dataMale (No., %)10 (50)9 (40.9)0.554Age (years) (Mean ± SD)15 ± 3.2313.77 ± 2.450.122Laboratory dataHbF (%) (Median, IQR)22.55 (15.25 to 41.55)22 (14.9 to 31.5)0.98Hemoglobin (g/dl) (Mean ± SD)7.94 ± 1.287.49 ± 0.840.262WBC (× 103/uL) (Mean ± SD)8.82 ± 5.0910.81 ± 10.940.521Platelets (× 103/uL) (Mean ± SD)659.4 ± 308.73563.64 ± 387.240.217Reticulocytic count (%)(Mean ± SD)5.45 ± 2.393.80 ± 1.500.027*TSB (mg/dL) (Mean ± SD)1.94 ± 0.561.92 ± 0.660.928DSB (mg/dL) (Mean ± SD)0.4 ± 0.130.42 ± 0.210.897LDH(U/L) (Mean ± SD)389.2 ± 134.23382.95 ± 144.000.650AST(U/L) (Mean ± SD)37.10 ± 13.9233.5 ± 20.770.164ALT(U/L) (Mean ± SD)22.65 ± 17.419.59 ± 8.510.930Creatinine (mg/dL) (Mean ± SD)0.53 ± 0.140.49 ± 0.1110.356RBS (mg/dL) (Mean ± SD)89.80 ± 11.9090.91 ± 10.810.753TreatmentHydroxyurea dose(mg/kg/day) (mean ± SD)17.9 ± 6.3419.27 ± 3.090.463HbF fetal hemoglobin, WBC white blood cells, BUN blood urea nitrogen, RBS random blood sugar, TSB total serum bilirubin, DSB direct serum bilirubin, LDH lactate dehydrogenase, AST aspartate transaminase, ALT alanine transaminase, IQR interquartile range*P-value considered significant if < 0.05
Source: Baseline Data of Included Subjects. View original paper
Relevance classification does not establish study quality, causation or editorial approval.
Study design Case-control study.
Case-control study
Compares people with an outcome against people without it, examining exposures.
Meta-analysis unclear · Blinding unclear / not reported · Human research reported
How this paper was classified
Automatic source-based classification; awaiting editorial verification. This is not a quality score.
This is a prospective interventional case: control study that was conducted at the Pediatric Hematology Clinic of Cairo University Children Hospital.
Source: Methods.
Patients were enrolled in the study after obtaining willingly written informed consent from the adult patients (above 18 years of age) and from the parents or guardians of the adolescent participants (12 to 17 years of age).
Source: Methods.
What the study types mean
- Systematic review
- Uses explicit methods to identify, assess and summarise research on a defined question.
- Scoping review
- Maps the extent and characteristics of research on a topic.
- Narrative review
- Discusses existing research; systematic-review methods have not been established by this classification.
- Review / evidence synthesis
- Reviews existing research; the exact review methods need further assessment.
- Randomised controlled trial
- Assigns participants or groups to comparison interventions by chance.
- Non-randomised intervention study
- Examines an intervention without random allocation.
- Cohort study
- Examines exposures and outcomes over time within a defined group.
- Case-control study
- Compares people with an outcome against people without it, examining exposures.
- Cross-sectional study
- Examines a population at a particular point in time.
- Observational study
- Observes exposures and outcomes without assigning the exposure; the subtype is not established here.
- Case report
- Describes an individual case.
- Case series
- Describes a group of individual cases.
- Secondary analysis
- Analyses existing study data; this paper is not automatically another independent trial.
- Laboratory study
- Investigates biological processes in a laboratory setting.
- Qualitative study
- Examines experiences or meanings using qualitative methods.
- Genetic instrumental-variable study
- Uses genetic variation as an instrument to investigate relationships; this is not a randomised treatment trial.
- Study protocol
- Describes planned methods and is not evidence that the planned study has reported results.
- Multiple reported designs
- More than one design is explicitly reported; examine the supporting methods.
- Study design awaiting verification
- The available source does not establish a sufficiently clear study design.
Meta-analysis combines numerical results from studies. Blinding describes who was unaware of treatment allocation. Neither is a separate quality grade. Study design, vitamin D relevance and document format are independent filters.
Abstracts
Metformin as a Fetal Hemoglobin Inducer in Non-transfusion Dependent Thalassemia Patients
Case-control study · Indian Journal of Hematology & Blood Transfusion · 2023
Original publication title
Metformin as a Fetal Hemoglobin Inducer in Non-transfusion Dependent Thalassemia Patients
© The Author(s) 2023
Original publication · Publisher record · CC BY 4.0
Source wording retained. Formatting, section navigation and display-title punctuation adapted for this research record.
At a glance
What does the authors’ abstract report?
Non-transfusion dependent thalassemia (NTDT) refers to a group of thalassemic disorders who do not need regular transfusions for survival, however it may be needed in certain conditions. Metformin was reported as a potential fetal hemoglobin (HbF) inducing agent in vitro but its efficacy and safety in vivo was not fully studied. This is a prospective interventional study aimed at studying the effect of metformin on HbF change in NTDT. Methods: Patients with established diagnosis of NTDT were enrolled. They were receiving a stable fixed dose of Hydroxyurea over the last 3 months.
Patients were divided into two groups: a group that received Metformin for 6 months (Metformin group) and a control group. Complete blood picture, reticulocytic count, hemoglobin electrophoresis, liver enzymes, bilirubin, kidney functions, LDH and random blood sugar were performed at onset, 3 and 6 months of the study. All adverse events were recorded. Results: Forty two patients aged 12 to 23 years were enrolled. Metformin intake over 6 months did not show any statistically significant difference in clinical or the laboratory variables of efficacy when compared to the control group apart from reticulocytic count which was higher in Metformin group throughout the study.
Conclusion: Metformin intake, in addition to hydroxyurea, did not yield any extra benefit among patients with NTDT.
Authors’ abstract
Non-transfusion dependent thalassemia (NTDT) refers to a group of thalassemic disorders who do not need regular transfusions for survival, however it may be needed in certain conditions. Metformin was reported as a potential fetal hemoglobin (HbF) inducing agent in vitro but its efficacy and safety in vivo was not fully studied. This is a prospective interventional study aimed at studying the effect of metformin on HbF change in NTDT. Methods: Patients with established diagnosis of NTDT were enrolled. They were receiving a stable fixed dose of Hydroxyurea over the last 3 months.
Patients were divided into two groups: a group that received Metformin for 6 months (Metformin group) and a control group. Complete blood picture, reticulocytic count, hemoglobin electrophoresis, liver enzymes, bilirubin, kidney functions, LDH and random blood sugar were performed at onset, 3 and 6 months of the study. All adverse events were recorded. Results: Forty two patients aged 12 to 23 years were enrolled. Metformin intake over 6 months did not show any statistically significant difference in clinical or the laboratory variables of efficacy when compared to the control group apart from reticulocytic count which was higher in Metformin group throughout the study.
Conclusion: Metformin intake, in addition to hydroxyurea, did not yield any extra benefit among patients with NTDT.
Publication and source details
Original title: Metformin as a Fetal Hemoglobin Inducer in Non-transfusion Dependent Thalassemia Patients
Mona ElTagui; Mona El-Ghamrawy; Shareef Karam AlDeeb; Mariam Saad Nassim
Indian Journal of Hematology & Blood Transfusion · 2023
© The Author(s) 2023https://creativecommons.org/licenses/by/4.0/Open AccessThis article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/.Kasr El-Aini HospitalOpen access funding provided by The Science, Technology & Innovation Funding Authority (STDF) in cooperation with The Egyptian Knowledge Bank (EKB).
Repository JATS snapshot; version as supplied
Source retrieved: 2026-11-11T19:25:27.785192+00:00
DOI: 10.1007/s12288-023-01662-1 · PMC10831011